Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint ...

Our Take on LLY’s Q4 Results. Lilly’s fourth-quarter results were rather uneventful, with the company already announcing preliminary sales numbers and 2025 sales outlook last month.

Eli Lilly and Company (NYSE:LLY) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ETCompany Participants. Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Eli Lilly (NYSE:LLY) reported strong Q4 2024 results on Thursday, surpassing Wall Street estimates, driven by a more than twofold increase in sales of its weight loss and diabetes drugs Mounjaro ...

The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $2.46 per share, indicating an increase of 17.7% compared to the year-ago period.

Despite the big rally in LLY stock, analysts forecast more gains ahead. The median price target on the company’s shares is currently $600, 12% higher than the current trading price. Pfizer (PFE) ...

JPMorgan analyst Chris Schott says Eli Lilly’s (LLY) Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidance ...